Establishing Reliable TB Reagent Quality Control in Australia

A tuberculosis laboratory reagent quality control program verifies that stains, media, molecular kits, enzymes, buffers and other critical materials are fit for use before patient results depend on them. The program should define what is checked, who checks it, when testing occurs, which results are acceptable and what happens when a lot fails.

For Australian laboratories, this work sits within a broader quality management system and should align with manufacturer instructions, local laboratory procedures and the requirements applied by NATA-accredited facilities. A sound process also supports reliable testing across metropolitan services, regional hospitals and remote clinics where supply delays, transport conditions and limited storage space can affect reagent performance.

Acceptance criteria need to be measurable wherever possible. A smear stain may need to produce clear differentiation between positive and negative controls; a culture medium may require documented sterility and expected growth; a molecular reagent may need valid internal controls and correct results for known reference materials. “Looks acceptable” is rarely enough for a defensible release decision.

The GLI Quality Tool provides a practical structure for organising this work through its quality systems essentials, phase-based checklists and downloadable resources. Reagent control is connected to equipment, purchasing, inventory, documentation, assessment, personnel competency and continual improvement, so it should be managed as a system rather than as an isolated bench task.

Reagent or material	Verification activity	Example acceptance criteria	Action if unacceptable
AFB staining reagents	Test known positive and negative control slides	Expected staining intensity, contrast and morphology are observed	Quarantine lot, investigate and repeat with approved controls
Culture media	Sterility check and growth promotion test	No contamination in sterility controls; target organism grows as specified	Do not release; notify supplier and assess affected cultures
Molecular assay kit	Run positive, negative and internal controls	Controls fall within kit or validated laboratory ranges	Reject run or lot, review storage and instrument conditions
Decontamination reagents	Check concentration, expiry and preparation record	Concentration is within validated range and preparation is traceable	Discard or remake; assess specimens processed with the reagent
DST materials	Test reference strains or panels	Results match expected susceptibility profile within defined limits	Stop reporting, review batch and notify the quality manager

Define the control points

Begin with a reagent register covering every material that can influence a TB result. Include Ziehl–Neelsen or auramine stains, microscopy oil, culture media, decontamination solutions, identification reagents, nucleic acid extraction materials, amplification kits, controls and drug susceptibility testing supplies. Record the supplier, catalogue number, lot number, expiry date, storage range, date received and person responsible for release.

Classify materials according to risk. A reagent that directly determines whether Mycobacterium tuberculosis complex is detected needs tighter lot acceptance than a low-risk cleaning solution. Consider the consequence of failure, the likelihood of degradation, the test volume and whether an alternative method is available. This helps a laboratory focus verification effort where it protects patients most effectively.

Set control points at receipt, before first use, after a significant storage event and during routine testing. A new lot should not be placed into general use simply because the box arrived intact. Packaging damage, temperature excursions, missing certificates, unclear labelling or a short remaining shelf life should trigger review before acceptance.

Write measurable acceptance criteria

Acceptance criteria should state the test, the control material, the expected result, the allowable range and the decision-maker. For example, a molecular assay lot might be accepted when a positive control crosses the manufacturer’s stated threshold, a negative control remains negative and internal controls pass in every applicable reaction. The laboratory must document any locally validated range rather than relying on an informal target.

For staining reagents, criteria can include a defined score for background cleanliness, organism visibility, counterstain contrast and absence of precipitate. For culture media, specify the organisms or reference strains used, incubation conditions, sterility expectations and minimum growth performance. For DST, define the reference strain, expected result and acceptable deviation before testing patient isolates.

Manufacturer instructions are the starting point, not always the complete local procedure. If a supplier gives a qualitative requirement, the laboratory can strengthen it with a documented visual scale, control image or comparison to a previously approved lot. Any locally developed criterion should be validated, approved and reviewed when the method, instrument or reagent formulation changes.

A simple release form should include “accepted”, “rejected” or “conditional use” with a reason. Conditional use should be exceptional, time-limited and approved by an authorised person. It should never become a way to bypass failed controls when urgent testing is requested.

Verify, store and monitor each lot

At receipt, inspect the shipment against the purchase order and packing documentation. Check seals, temperature indicators where supplied, transport time, expiry dates and lot identifiers. In Australia, a reagent travelling from a mainland distributor to a regional service or across the Top End may experience long transport intervals and seasonal heat. Storage records should demonstrate that the material reached the required conditions promptly.

Use dedicated temperature monitoring for refrigerators, freezers and rooms where reagent performance depends on environmental control. Record minimum and maximum values, review excursions and link them to affected lots. A “no worries” approach to a brief excursion can create a serious traceability gap; the correct response is a documented risk assessment based on product information and duration.

Test a new lot against an old, approved lot when both are available, using suitable positive and negative controls. This comparison can reveal a gradual change that a single control might miss. For molecular assays, include the required kit controls and, where appropriate, a characterised external material. For culture and microscopy, use stable reference strains, control slides or other materials that are handled consistently.

Trend the results rather than filing them away. A gradual fall in control signal, increasing contamination, frequent invalid runs or repeated staining variation may indicate deterioration before a formal failure occurs. The quality officer should review these patterns at a defined interval and escalate them through the laboratory’s corrective action process.

Manage failures and incidents

When a reagent fails its acceptance criteria, stop routine use, label it clearly and quarantine the affected lot. Do not discard it before the investigation is complete unless safety requires immediate disposal. Check preparation records, storage temperatures, equipment status, operator competency, control material integrity and the possibility of transcription or calculation errors.

Determine whether patient specimens were tested with the suspect material. If so, identify the dates, runs, operators and reported results that may be affected. The laboratory director or designated quality lead should decide whether testing must be repeated, reports amended or clinicians and public health contacts notified. Australian TB services may need to coordinate across state or territory networks when a referral laboratory or shared testing pathway is involved.

Record the event in a controlled incident or nonconformance system. Clear documentation of the problem, immediate containment, risk assessment, root cause, corrective action and effectiveness check protects patients and supports learning. Practical incident reporting guidance can help laboratories create consistent records instead of relying on scattered emails or handwritten notes.

A supplier complaint should include the product name, lot, expiry, evidence of failure, storage history and affected testing. Keep correspondence and replacement details with the investigation. Repeated failures from one source should influence procurement decisions and may justify an approved alternative, additional verification or a review of contract conditions.

Connect the program to accreditation

Assign responsibilities clearly. Bench staff may perform receipt checks and control testing, while a senior scientist reviews results and the quality manager authorises release. The laboratory director retains oversight of patient risk. Each person should be trained in the relevant procedure and demonstrate competency before working independently.

Keep records that an auditor can follow from purchase to patient testing. A complete trail includes the purchase order, receipt inspection, storage log, verification results, approval, in-use monitoring, incidents and final disposal. Electronic systems can improve retrieval, provided access controls, audit trails and backup arrangements are maintained.

Use internal audits to sample real lots and confirm that staff followed the procedure. Review whether acceptance criteria remain appropriate after a platform change, a new supplier, a revised kit insert or an incident. Preparation for external review is easier when evidence is current; laboratories can use WHO SLMTA assessment guidance to connect reagent controls with wider quality management expectations.

The GLI Quality Tool’s four-phase roadmap can help a laboratory move from informal checks to a controlled, measured programme. Start with an inventory and risk assessment, then build approved procedures, train staff, monitor performance and use audit findings to strengthen the system. The result should be practical for a busy Sydney laboratory, a regional Queensland service or a remote Northern Territory facility operating with longer supply chains and fewer backup options.

Download the relevant GLI Quality Tool checklists, nominate an accountable quality lead and review every critical TB reagent against documented acceptance criteria. Quarantine unresolved lots, verify approved materials before use and make each decision traceable from delivery through final result.